ATS 2020: long-term noninvasive ventilation in stable hypercapnic COPD

Who it applies to

Adults with chronic stable COPD who have chronic hypercapnic respiratory failure, including those recently discharged after an exacerbation-related hospitalization.

Key recommendations

• Long-term NIV is suggested for stable hypercapnic COPD patients in addition to usual care, rather than usual care alone.
  Conditional, moderate quality of evidence
• For patients hospitalized with an acute exacerbation who have persistent hypercapnia (checked roughly 2-4 weeks after resolution of the acute episode), long-term NIV is suggested rather than no NIV.
  Conditional, low quality of evidence
• The panel suggests a strategy targeting higher inspiratory pressures aimed at substantially reducing carbon dioxide levels rather than lower-pressure approaches.
  Conditional, low quality of evidence
• Screening for coexisting obstructive sleep apnea is suggested in candidates being considered for home NIV, since comorbid OSA may change management.
  Conditional, very low quality of evidence
• The guideline emphasizes that patient selection should focus on documented hypercapnia in the stable state rather than relying on hypercapnia detected only during an acute exacerbation.
• Decisions about initiating long-term NIV should take into account patient goals, comorbidities, and feasibility of home ventilator management and follow-up.
• The panel highlights that evidence quality overall is low to moderate, reflecting small trial sizes, heterogeneity in ventilator settings, and variable patient selection criteria across studies.
• Benefits considered include possible reductions in hospitalizations, improved gas exchange, and in some studies improved survival, weighed against burdens of home ventilation therapy.

What is new in this edition

• First dedicated ATS guideline focused specifically on long-term home NIV in stable hypercapnic COPD, distinguishing this population from acute exacerbation-related NIV use.
• Introduces a conditional recommendation for a high-intensity NIV strategy targeting significant reduction in carbon dioxide rather than only symptom relief or lower pressure settings.

Practice points for students

• Distinguish acute NIV use during exacerbations from long-term home NIV for chronic stable hypercapnic COPD, which this guideline specifically addresses.
• Confirm hypercapnia persists in the stable state, generally reassessed several weeks after an exacerbation, before committing to long-term NIV.
• Consider screening for obstructive sleep apnea before starting home NIV, since overlap syndrome may alter ventilator strategy.
• Higher-intensity NIV settings aimed at meaningfully lowering CO2 are favored over low-pressure, comfort-only approaches.
• All recommendations are conditional, based on evidence ranging from low to moderate quality, so shared decision-making with patients is essential.

Condition

Other guidelines on this topic

• 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPDCHEST2023Summary
• Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)NICE2019Summary
• Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineERS2017Summary

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by ATS. It is not medical advice: always read the original guideline before applying it to patients.